Update shared on 11 Dec 2025
Narrative Update on Health Catalyst Analyst Price Target
Analysts have modestly raised their price target on Health Catalyst by approximately 4 percent to around 3.94 dollars. This reflects slight adjustments to the discount rate and future earnings expectations, while views on revenue growth and profit margins remain largely unchanged.
What's in the News
- Issued new revenue guidance for the fourth quarter of 2025, projecting approximately 73.5 million dollars in total revenue (company guidance)
- Provided full-year 2025 outlook, forecasting approximately 310 million dollars in total revenue (company guidance)
Valuation Changes
- Fair Value: Unchanged at approximately 3.94 dollars, indicating a stable intrinsic value estimate.
- Discount Rate: Risen slightly from about 10.50 percent to roughly 10.68 percent, reflecting a modestly higher required return.
- Revenue Growth: Essentially unchanged, edging down marginally from about 31.00 percent to 30.999 percent.
- Net Profit Margin: Stable at around 7.11 percent, with no meaningful revision to long term profitability assumptions.
- Future P/E: Risen slightly from about 16.91 times to roughly 16.99 times, suggesting a marginally higher valuation multiple on forward earnings.
Have other thoughts on Health Catalyst?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.